| | |  | | | | Record from Web of Science® | |  |  | | |  |
| Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) |
|
|
| Author(s): Furberg CD, Wright JT, Davis BR, Cutler JA, Alderman M, Black H, Cushman W, Grimm R, Haywood LJ, Leenen F, Oparil S, Probstfield J, Whelton P, Nwachuku C, Gordon D, Proschan M, Einhorn P, Ford CE, Piller LB, Dunn JK, Goff D, Pressel S, Bettencourt J, deLeon B, Simpson LM, Blanton J, Geraci T, Walsh SM, Nelson C, Rahman M, Juratovac A, Pospisil R, Carroll L, Sullivan S, Russo J, Barone G, Christian R, Feldman S, Lucente T, Calhoun D, Jenkins K, McDowell P, Johnson J, Kingry C, Alzate J, Margolis KL, Holland-Klemme LA, Jaeger B, Williamson J, Louis G, Ragusa P, Williard A, Ferguson RLS, Tanner J, Eckfeldt J, Crow R, Pelosi J |
| Source: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION Volume: 288 Issue: 23 Pages: 2981-2997 Published: DEC 18 2002 |
| Times Cited: 1,902 References: 55 |
| Abstract: Context Anti hypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown. Objective To determine whether treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic.
Design The Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, active-controlled clinical trial conducted from February 1994 through March 2002.
Setting and Participants A total of 33 357 participants aged 55 years or older with hypertension and at least 1 other CHD risk factor from 623 North American centers.
Interventions Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n= 15255); amlodipine, 2.5 to 10 mg/d (n =9048); or lisinopril, 10 to 40 mg/d (n=9054) for planned follow-up of approximately 4 to 8 years.
Main Outcome Measures The primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intent-to-treat. Secondary outcomes were all-cause mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure [HF], and peripheral arterial disease).
Results Mean follow-up was 4.9 years. The primary outcome occurred in 2956 participants, with no difference between treatments. Compared with chlorthaliclone (6-year rate, 11.5%), the relative risks (RRs) were 0.98 (95% Cl, 0.90-1.07) for amlodipine (6-year rate, 11.3%) and 0.99 (95% Cl, 0.91-1.08) for lisinopril (6-year rate, 11.4%). Likewise, all-cause mortality did not differ between groups. Five-year systolic blood pressures were significantly higher in the amlodipine (0.8 mm Hg, P=.03) and lisinopril (2 mm Hg, P<.001) groups compared with chlorthaliclone, and 5-year diastolic blood pressure was significantly lower with amlodipine (0.8 mm Hg, P<.001). For amlodipine vs chlorthaliclone, secondary outcomes were similar except for a higher 6-year rate of HF with amlodipine (10.2% vs 7.7%; RR, 1.38; 95% Cl, 1.25-1.52). For lisinopril vs chlorthaliclone, lisinopril had higher 6-year rates of combined CVD (33.3% vs 30.9%; RR, 1.10; 95% Cl, 1.05-1.16); stroke (6.3% vs 5.6%; RR, 1.15; 95% Cl, 1.02-1.30); and HF (8.7% vs 7.7%; RR, 1.19; 95% Cl, 1.07-1.31).
Conclusion Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy.
|
| Document Type: Article |
| Language: English |
| Reprint Address: Wright, JT (reprint author), Case Western Reserve Univ, Gen Clin Res Ctr, Suite 7311,Horvitz Tower,11000 Euclid Ave, Cleveland, OH 44106 USA |
Addresses:
1. Case Western Reserve Univ, Gen Clin Res Ctr, Cleveland, OH 44106 USA |
| Publisher: AMER MEDICAL ASSOC, 515 N STATE ST, CHICAGO, IL 60610 USA |
| Subject Category: Medicine, General & Internal |
| IDS Number: 626CG |
| ISSN: 0098-7484 |
|
| |  |  |  |  | | | | Record from Web of Science® | |  |  | | | | | | |